Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
XTX301 in Patients With Advanced Solid Tumors
NCT05684965
Recruiting
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Advanced Solid Tumor
Register for Updates
A Novel Program Using Ride-on Toys to Improve Upper Extremity Function in Children With Hemiplegia
NCT06579027
Recruiting
The purpose of this study is to assess the feasibility and utility of 2 types of play-based training programs co-delivered by researchers and caregivers within home/community settings to promote arm function among 3-to-8-year-old children with hemiplegia. Specifically, investigators will assess the feasibility of implementation and acceptance/satisfaction associated with a researcher-caregiver co-delivered community-based training program involving either joystick-operated powered ride-on toys (... Read More
Gender:
ALL
Ages:
Between 3 years and 8 years
Trial Updated:
06/04/2025
Locations: Physical Therapy Program, Department of Kinesiology, University of Connecticut, Storrs, Connecticut
Conditions: Hemiplegia, Cerebral Palsy, Children, Only
Register for Updates
The Impact of Blood Flow Restriction Training in Adolescents After ACL Reconstruction: A Randomized Controlled Trial
NCT05754632
Recruiting
While there are a number studies that have reported on the use of blood flow restriction training (BFRT) in the adult population, there is limited information about the use of BFRT in the adolescent population. This study aims to evaluate the use of BFRT in conjunction with traditional anterior ligament reconstruction (ACLR) rehabilitation in adolescents. The purpose of this study is to compare the addition of a BFRT based exercise protocol to a standard ACL rehabilitation protocol in adolescen... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
06/04/2025
Locations: Connecticut Children's Sports Physical Therapy, Farmington, Connecticut
Conditions: Anterior Cruciate Ligament Injuries, Knee Injuries, Quadriceps Muscle Atrophy
Register for Updates
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055
Recruiting
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Stamford Therapeutics Consortium, Stamford, Connecticut
Conditions: SARS-CoV2, COVID-19
Register for Updates
Neurologic Stem Cell Treatment Study
NCT02795052
Recruiting
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: MD Stem Cells, Westport, Connecticut
Conditions: Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Register for Updates
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738
Recruiting
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be give... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Clinical Trial Site, New Haven, Connecticut
Conditions: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Register for Updates
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
NCT06292923
Recruiting
Foralumab is a human anti-CD3 monoclonal antibody being developed for the treatment of autoimmune and inflammatory diseases. The goal of this Phase 2a, randomized, double-blind placebo-controlled, multicenter dose-ranging study is to evaluate the use of nasal foralumab in patients with non-active secondary progressive multiple sclerosis (SPMS). The primary objectives that this study aims to answer are: 1. To determine the safety and tolerability of 50 μg/dose and 100 μg/dose of foralumab nasa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Yale, North Haven, Connecticut
Conditions: Secondary Progressive Multiple Sclerosis
Register for Updates
OssDsign® Spine Registry Study ("Propel")
NCT05329129
Recruiting
The purpose of this multi-center, prospective, observational registry is to gather information on the clinical outcomes and real-world use of commercially available bone graft substitutes manufactured by OssDsign® AB, in patients who require spine fusion.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/03/2025
Locations: Orthopedic Associates of Hartford, Hartford, Connecticut
Conditions: Degenerative Disc Disease, Spinal Stenosis
Register for Updates
Echography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure
NCT06446453
Recruiting
Point-of-care ultrasound (POCUS) is the use of ultrasound by the bedside provider in real time to answer a specific question and guide medical management. POCUS can be used to diagnose the severity of neonatal respiratory distress syndrome (RDS) through a lung ultrasound score. Lung ultrasound scores have also been shown to predict if an infant is treated with an initial dose of surfactant. Therefore, using lung ultrasound scores to guide surfactant therapy for RDS will likely lead to earlier su... Read More
Gender:
ALL
Ages:
Between 0 hours and 2 hours
Trial Updated:
06/03/2025
Locations: Connecticut Children's, Hartford, Connecticut
Conditions: Respiratory Distress Syndrome, Newborn, Pulmonary Surfactants, Intensive Care Units, Neonatal
Register for Updates
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
NCT05735184
Recruiting
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Yale Cancer Center and Smilow Cancer Hospital, New Haven, Connecticut
Conditions: Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
Register for Updates
tDCS for Laryngeal Dystonia
NCT06830174
Recruiting
This project will apply transcranial direct current stimulation (tDCS) to multiple brain areas to evaluate the effects as a potential treatment for laryngeal dystonia (formerly spasmodic dysphonia).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/02/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Laryngeal Dystonia
Register for Updates
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
NCT03328078
Recruiting
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies. This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut
Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Register for Updates